Wednesday, May 24, 2023
ClearPoint Neuro announced that it has entered into a multi-year licence agreement with UCB to partner on drug delivery platforms for UCB’s gene therapy portfolio.
Under the terms of the licence agreement, UCB will utilise ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialisation of UCB’s gene therapy products. ClearPoint Neuro will receive success-based milestone payments.
This partnership with UCB, will focus on innovation through the adoption of next generation science and new technologies. ClearPoint Neuro enables to become a strong strategic fit for UCB committed to dedicated innovation in the neurology space with a unique portfolio of navigation and drug delivery tools.
